News
-
Ineke Muir heads the Vascular Biophysics team, CSL Research. She investigates the effects of shear forces on preclinical drugs and therapies, to predict how they will behave in the bloodstream. She’s also a mum, an avid bike rider and an occasional bookworm.
-
Michael Parker and Craig Morton, St Vincent’s Institute of Medical Research (SVI) in Melbourne Australia, and Bio21 Institute are part of an international team of collaborators that has made a discovery that may lead to more effective treatment and less side effects for a number of cancers including neuroblastoma, a cancer that occurs most commonly in infants and children under 5 years of age.
-
A phase 1 human clinical trial of a compound developed by Paul Donnelly, School of Chemistry and Kevin Barnham (Florey Institute of Neuroscience and Mental Health) whilst at the Bio21 Molecular Science and Biotechnology Institute and Anthony White, University of Melbourne and is showing promise in alleviating the symptoms of Parkinson’s disease.
-
Bio21's Professor Emeritus Frances Separovic, Deputy Director of the Bio21 Institute has been honoured with the appointment as an Officer (AO) of the Order of Australia (General Division) announced in the Queen's Birthday 2019 Honours List on 10 June 2019.
Frances has been awarded an AO for her distinguished service to science education, particularly to biophysical chemistry, as an academic, and to young women scientists.
-
Read about Dr Zalihe (Zal) Hakki, Chemistry, Williams Group, developing drugs against steroid-resistant asthma
-
Read about Qiong Yang (Yang), Research Fellow at the Pest & Environmental Adaptation Research Group (PEARG) at Bio21.
-
Bio21's Isabelle Rouiller, as part of an international team, has used powerful Cryo-EM microscopy to discover how small molecules can be used to ‘open up’ the HIV virus – allowing the immune system to target and destroy it.
-
Asmini Athman is the Lab Manager & OHS Advisor of the MDHS Infrastructure & Facilities team.
-
Read about Fiona Houghton, Dept Biochemistry and Molecular Biology, Bio21, Gleeson Lab
-
A new drug delays motor neurone disease progression and improves cognitive and clinical symptoms according to recently announced trial results.